Moreover, a Brazilian study using the Foundation One or Foundation ACT, described 5% of NSCLC patients harboring ERBB2 mutations (n = 26/513), with 1.4% (7/513) exhibiting the exon 20 insertions (p. A775_G776INSYVMA), but no additional information was reported.10 This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.